Debevoise & Plimpton LLP is advising Konica Minolta in the sale of its subsidiary, Ambry Genetics, to Tempus AI (NASDAQ: TEM) in which Tempus will acquire Ambry for $375 million in cash and $225 million in shares at closing, of which $100 million will be subject to a lock-up agreement until one year post-transaction close. For more information, please see the company’s press release.

Ambry is a genetic testing company. Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

The Debevoise team is led by M&A partner Andrew Bab and counsel Sergio Torres and includes associates Jason Zhang, Elina Sigal and Stephen Mattes, healthcare counsel Kim Le, finance partner Sunil Savkar and associate Lachlan Conroy, employee benefits and executive compensation counsel Sarah Burke, associate Simmie Jenkelowitz and law clerk Alexandra Schoellkopf, intellectual property counsel Tigist Kassahun and associates Matthew Anekstein, Melody Godbolt, Jarrett Lewis and Dylan Sanders, capital markets partner Morgan Hayes and associate Jason Auman, tax partner Michael Bolotin, counsel Ben Lee Friedman and associate David Simpser, antitrust partners Ted Hassi and Timothy McIver and counsel Kyra Bromley, regulatory partner Paul Rubin, counsel Melissa Runsten and associate Hannah Levine and environmental counsel Stuart Hammer.